ONC 201 - Oncoceutics

Drug Profile

ONC 201 - Oncoceutics

Alternative Names: NSC-350625; ONC201; ONC201 - Oncoceutics; TIC 10; TRAIL-inducing compound 10 (TIC10) - Oncoceutics

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Oncoceutics
  • Developer Oncoceutics; Rutgers; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Extracellular signal-regulated MAP kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Mantle-cell lymphoma
  • Phase Unknown Neuroendocrine tumours

Most Recent Events

  • 12 Mar 2017 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (PO)
  • 25 Jan 2017 Investigation in Neuroendocrine tumours in USA (PO) before January 2017
  • 25 Jan 2017 Case Comprehensive Cancer Center plans a phase II trial for Neuroendocrine tumours, including pheochromocytoma-paraganglioma (Recurrent, Metastatic disease, Second-line or greater therapy) in USA (PO) (NCT03034200)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top